{
    "eid": "2-s2.0-85088869258",
    "title": "Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation",
    "cover-date": "2020-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "hepatitis B core antigen",
        "hepatitis B RNA",
        "hepatitis B surface antigen",
        "relapse"
    ],
    "authors": [
        "Apichat Kaewdech",
        "Pisit Tangkijvanich",
        "Pimsiri Sripongpun",
        "Teepawit Witeerungrot",
        "Sawangpong Jandee",
        "Yasuhito Tanaka",
        "Teerha Piratvisuth"
    ],
    "citedby-count": 23,
    "ref-count": 31,
    "ref-list": [
        "Chronic hepatitis B infection: a review",
        "Hepatitis B virus infection\u2013natural history and clinical consequences",
        "Clinical relevance of the study of hepatitis B virus covalently closed circular DNA",
        "HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B",
        "Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis",
        "Discontinuation of oral antivirals in chronic hepatitis B: a systematic review",
        "Clinical practice guidelines on the management of hepatitis B virus infection",
        "AASLD guidelines for treatment of chronic hepatitis B",
        "The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review",
        "Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection",
        "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy",
        "Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B",
        "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk",
        "Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection",
        "Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors",
        "Serum HBV RNA as a predictor of peginterferon Alfa-2a response in patients with HBeAg-positive chronic hepatitis B",
        "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound",
        "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update",
        "Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B",
        "Reverse transcriptase droplet digital PCR versus reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification",
        "Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy",
        "Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy",
        "Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies",
        "Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA",
        "Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B",
        "Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study",
        "Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B",
        "The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B",
        "Can we stop nucleoside analogues before HBsAg loss?",
        "Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B",
        "Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hatyai",
            "@id": "60028394",
            "affilname": "Songklanagarind Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028394",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nagoya",
            "@id": "60004321",
            "affilname": "Nagoya City University Graduate School of Medical Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004321",
            "affiliation-country": "Japan"
        }
    ],
    "funding": [
        "Center of Excellence in Hepatitis and Liver Cancer",
        "Thai Association",
        "Abbott Laboratories",
        "Chulalongkorn University",
        "Thailand Research Fund",
        "Faculty of Medicine, Prince of Songkla University"
    ]
}